河北医科大学学报

• 论著 • 上一篇    下一篇

雷替曲塞联合奥沙利铂二线治疗晚期贲门癌的疗效观察

  

  1. 1.河北医科大学第四医院胸外五科,河北 石家庄 050091;2.河北医科大学第三医院干部病房,河北 石家庄 050051
  • 出版日期:2016-01-25 发布日期:2016-04-27
  • 作者简介:吕会来( 1980- ),男,河北宁晋人,河北医科大学第 四医院主治医师,医学博士,从事胸部肿瘤疾病诊治研究。

Effect of raltitrexed combined oxaliplantin as secondline chemotherapy for advanced gastric cardial carcinoma

  1. (1.Fifth Department of Thoracic Surgery,the Fourth Hospital of Hebei Medical University,
    Shijiazhuang 050091,China;2.Department of Cadre Ward,the Third Hospital of Hebei Medical University,Shijiazhuang,050011,China
  • Online:2016-01-25 Published:2016-04-27

摘要: 目的 雷替曲塞与奥沙利铂联合方案二线治疗晚期贲门癌的近期疗效和不良反应。方法 对 58 例经
过一线化疗之后出现复发进展的晚期贲门癌患者采用雷替曲塞联合奥沙利铂方案化疗,雷替曲塞 3mg / m
2
静脉滴
注联合奥沙利钠 130mg / m
2
静脉滴注,时间 >3h ,均为第 1 天给药,每 21d 为 1 周期, 2 周期后行胸腹部 CT 评价
疗效,并评价不良反应,最多 6 个周期。结果 58 例患者完全缓解 2 例( 3.4% ),部分缓解 16 例( 27.6% ),稳定 14
例( 24.1% ),疾病进展 26 例(
44.8% );总有效率为 31.0% ,临床获益率为 55.2% 。中位疾病进展时间 6.9 个月,主
要不良反应为骨髓抑制、恶心呕吐、转氨酶升高、周围神经毒性等,多为轻度,无治疗相关性死亡患者,也无因毒性
反应而推迟化疗者。结论 雷替曲塞联合奥沙利铂二线治疗复发转移的晚期贲门癌具有较好的疗效,耐受性好。

关键词: 胃肿瘤, 抗肿瘤联合化疗方案, 治疗结果

Abstract:  Objective Toevaluatetheefficiency andtoxicity ofraltitrexedcombined
qxaliplantinassecond-linechemotherapyintreatmentofadvancedgastriccardialcarcinoma.
Methods Fifty-eightpatientsofadvancedgastriccardialcarcinomawhohadreceivedfirst-line
therapybuthadrelapsedorprogressedweregiven3mg
/ m
2 ofraltitrexed ,
intravenousbolus ,
d1 , 21daysasacycle , combinedoxaliplantin130mg / m
2 ,
intravenousinfusion>3h , d1 , 21
daysasacycle.Theanalysislastedatleasttwocyclessoastoevaluatetheshort-termefficiency
andadversereactions.Aftertwocyclesofchemotherapy , theefficiencyandtoxicity were
evaluated.Atotalofsixcycleswereappliedunlesstherewereevidenceofdiseaseprogressionor
intoleranceoftreatment.Results All58patientswereevaluable , includingcompleteresponse2
cases , accountingfor3.4% , partialresponse16cases , accountingfor27.6% ; stabledisease14
cases , accountingfor24.1% ; progressivedisease26cases , 44.8%.Overallresponseratewas
31.0% , diseasecontrolrate55.2% , themiddletimetoprogression6.9months.Themainside
effects were myelosuppression , gastrointestinal reactions , aminotransferase abnormality ,
peripheralneurotoxicityandsoon.Thewholegrouphadnotreatment-relateddeathinpatients
and no toxicity due to the delay chemotherapy.Conclusion Raltitrexed as second-line chemotherapyintreatmentofadvancedgastriccardialcarcinomaiseffectiveandwelltolerated.

Key words: stomach neoplasms, antineoplastic combined chemotherapy protocols, treatment outcome